Financial Ratios NovoCure Limited
Equities
NVCR
JE00BYSS4X48
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.45 USD | -5.21% |
|
-1.39% | +4.02% |
| Jan. 14 | NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM | |
| Jan. 12 | NovoCure Reports Rise in Q4 Preliminary Revenue | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.51 | -2.49 | -4.77 | -12.09 | -8.77 | |||||
Return on Total Capital | 2.94 | -2.85 | -5.51 | -14.19 | -10.46 | |||||
Return On Equity % | 5.71 | -13.16 | -21.73 | -51.52 | -46.67 | |||||
Return on Common Equity | 5.71 | -13.16 | -21.73 | -51.52 | -46.67 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 78.54 | 78.65 | 78.76 | 74.96 | 77.5 | |||||
SG&A Margin | 45.6 | 49.19 | 56.97 | 75.97 | 70.59 | |||||
EBITDA Margin % | 7.8 | -6.45 | -14.75 | -42.5 | -26.05 | |||||
EBITA Margin % | 6.23 | -8.17 | -16.53 | -44.4 | -27.68 | |||||
EBIT Margin % | 6.23 | -8.17 | -16.53 | -44.4 | -27.68 | |||||
Income From Continuing Operations Margin % | 4.01 | -10.91 | -17.2 | -40.65 | -27.86 | |||||
Net Income Margin % | 4.01 | -10.91 | -17.2 | -40.65 | -27.86 | |||||
Net Avail. For Common Margin % | 4.01 | -10.91 | -17.2 | -40.65 | -27.86 | |||||
Normalized Net Income Margin | 2.17 | -6.04 | -10 | -25.94 | -16.16 | |||||
Levered Free Cash Flow Margin | 12.23 | 18.36 | 8.54 | -2 | 1.54 | |||||
Unlevered Free Cash Flow Margin | 13.55 | 18.13 | 8.32 | -2.25 | 1.98 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.65 | 0.49 | 0.46 | 0.44 | 0.51 | |||||
Fixed Assets Turnover | 12.97 | 11.2 | 8.76 | 6.11 | 5.57 | |||||
Receivables Turnover (Average Receivables) | 6.36 | 5.62 | 5.98 | 6.91 | 8.94 | |||||
Inventory Turnover (Average Inventory) | 4.15 | 4.41 | 4.25 | 3.78 | 3.72 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 8.8 | 7.53 | 7 | 5.78 | 1.46 | |||||
Quick Ratio | 8.38 | 7.29 | 6.73 | 5.46 | 1.37 | |||||
Operating Cash Flow to Current Liabilities | 0.87 | 0.58 | 0.19 | -0.41 | -0.03 | |||||
Days Sales Outstanding (Average Receivables) | 57.58 | 64.9 | 61.02 | 52.84 | 40.95 | |||||
Days Outstanding Inventory (Average Inventory) | 88.18 | 82.83 | 85.94 | 96.63 | 98.42 | |||||
Average Days Payable Outstanding | 150.94 | 207.11 | 241.58 | 240.44 | 274.24 | |||||
Cash Conversion Cycle (Average Days) | -5.17 | -59.38 | -94.63 | -90.97 | -134.87 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 94.58 | 141.76 | 133.77 | 166.75 | 189.72 | |||||
Total Debt / Total Capital | 48.61 | 58.64 | 57.22 | 62.51 | 65.48 | |||||
LT Debt/Equity | 93.22 | 140.13 | 132.45 | 164.48 | 32.56 | |||||
Long-Term Debt / Total Capital | 47.91 | 57.96 | 56.66 | 61.66 | 11.24 | |||||
Total Liabilities / Total Assets | 54.7 | 63.98 | 62.98 | 68.37 | 70.97 | |||||
EBIT / Interest Expense | 1.74 | -12.7 | -26.67 | -68.14 | -16.2 | |||||
EBITDA / Interest Expense | 2.52 | -7.9 | -21.67 | -62.75 | -14.35 | |||||
(EBITDA - Capex) / Interest Expense | 1.67 | -14.93 | -28.07 | -70.91 | -18.49 | |||||
Total Debt / EBITDA | 10.13 | -21.41 | -8.17 | -2.9 | -4.6 | |||||
Net Debt / EBITDA | -8.8 | 13.09 | 5.25 | 1.47 | 1.86 | |||||
Total Debt / (EBITDA - Capex) | 15.26 | -11.33 | -6.31 | -2.57 | -3.57 | |||||
Net Debt / (EBITDA - Capex) | -13.26 | 6.93 | 4.05 | 1.3 | 1.45 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 40.72 | 8.23 | 0.52 | -5.3 | 18.82 | |||||
Gross Profit, 1 Yr. Growth % | 47.61 | 8.38 | 0.66 | -9.86 | 22.85 | |||||
EBITDA, 1 Yr. Growth % | 522.87 | -189.54 | 129.8 | 172.81 | -27.16 | |||||
EBITA, 1 Yr. Growth % | -5.35K | -241.82 | 103.49 | 154.36 | -25.92 | |||||
EBIT, 1 Yr. Growth % | -5.35K | -241.82 | 103.49 | 154.36 | -25.92 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -373.97 | -394.58 | 58.58 | 123.75 | -18.55 | |||||
Net Income, 1 Yr. Growth % | -373.97 | -394.58 | 58.58 | 123.75 | -18.55 | |||||
Normalized Net Income, 1 Yr. Growth % | -258.8 | -400.91 | 66.33 | 145.66 | -25.99 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -342.09 | -413.41 | 56.72 | 120.55 | -19.81 | |||||
Accounts Receivable, 1 Yr. Growth % | 64.29 | -3.24 | -7.81 | -29.03 | 21.24 | |||||
Inventory, 1 Yr. Growth % | 15.7 | -10.92 | 20.26 | 29.87 | -8.04 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 20.34 | 29.42 | 27.98 | 41.68 | 22.41 | |||||
Total Assets, 1 Yr. Growth % | 119.42 | 8.32 | 4.58 | -3.82 | 8.26 | |||||
Tangible Book Value, 1 Yr. Growth % | 118.8 | -13.86 | 7.47 | -17.83 | -0.64 | |||||
Common Equity, 1 Yr. Growth % | 118.8 | -13.86 | 7.47 | -17.83 | -0.64 | |||||
Cash From Operations, 1 Yr. Growth % | 272.46 | -16.53 | -62.8 | -338.2 | -64.04 | |||||
Capital Expenditures, 1 Yr. Growth % | 42.76 | 61.48 | -11.63 | 26.85 | 58.18 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 142.81 | 46.63 | -56.19 | -119.71 | -570.31 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 100.45 | 32.08 | -56.85 | -122.63 | -472.88 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 41.17 | 23.41 | 4.3 | -2.43 | 6.08 | |||||
Gross Profit, 2 Yr. CAGR % | 51.86 | 26.48 | 4.45 | -4.75 | 5.23 | |||||
EBITDA, 2 Yr. CAGR % | 22.25 | 136.16 | 43.44 | 150.39 | 40.97 | |||||
EBITA, 2 Yr. CAGR % | -3.84 | 762.76 | 69.88 | 127.51 | 37.27 | |||||
EBIT, 2 Yr. CAGR % | -3.84 | 762.76 | 69.88 | 127.51 | 37.27 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -44.17 | 184.09 | 116.14 | 88.37 | 34.99 | |||||
Net Income, 2 Yr. CAGR % | -44.17 | 184.09 | 116.14 | 88.37 | 34.99 | |||||
Normalized Net Income, 2 Yr. CAGR % | -39.88 | 118.6 | 123.72 | 102.14 | 34.84 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -49 | 175.45 | 121.63 | 85.92 | 32.99 | |||||
Accounts Receivable, 2 Yr. CAGR % | 62.72 | 26.08 | -5.55 | -19.11 | -7.24 | |||||
Inventory, 2 Yr. CAGR % | 10.26 | 1.52 | 3.5 | 24.98 | 9.29 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 64.61 | 24.8 | 28.7 | 34.65 | 31.69 | |||||
Total Assets, 2 Yr. CAGR % | 75.95 | 54.16 | 6.43 | 0.29 | 2.04 | |||||
Tangible Book Value, 2 Yr. CAGR % | 106.03 | 37.29 | -3.78 | -6.03 | -9.64 | |||||
Common Equity, 2 Yr. CAGR % | 106.03 | 37.29 | -3.78 | -6.03 | -9.64 | |||||
Cash From Operations, 2 Yr. CAGR % | 629.13 | 76.32 | -44.28 | -5.86 | -7.45 | |||||
Capital Expenditures, 2 Yr. CAGR % | 49.34 | 51.83 | 19.45 | 5.87 | 41.65 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 103.37 | 98.62 | -17.17 | -68.82 | -57.63 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 74.45 | 70.41 | -21.95 | -66.79 | -51.3 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 40.82 | 29.2 | 15.25 | 1 | 4.19 | |||||
Gross Profit, 3 Yr. CAGR % | 47.25 | 35.71 | 17.21 | -0.56 | 3.68 | |||||
EBITDA, 3 Yr. CAGR % | 5.67 | 10.2 | 134.02 | 77.72 | 65.91 | |||||
EBITA, 3 Yr. CAGR % | -7.66 | 9.45 | 433.06 | 94.34 | 56.52 | |||||
EBIT, 3 Yr. CAGR % | -7.66 | 9.45 | 433.06 | 94.34 | 56.52 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -31.51 | -2.81 | 133.91 | 118.65 | 42.44 | |||||
Net Income, 3 Yr. CAGR % | -31.51 | -2.81 | 133.91 | 118.65 | 42.44 | |||||
Normalized Net Income, 3 Yr. CAGR % | -29.54 | 2.84 | 99.57 | 130.81 | 44.61 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -36.3 | -6.59 | 128.25 | 121.27 | 40.47 | |||||
Accounts Receivable, 3 Yr. CAGR % | 48.44 | 36.83 | 13.59 | -14.13 | -7.43 | |||||
Inventory, 3 Yr. CAGR % | 7.58 | 2.69 | 7.42 | 11.64 | 12.83 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 32.09 | 51.93 | 25.85 | 32.89 | 30.44 | |||||
Total Assets, 3 Yr. CAGR % | 58.28 | 49.68 | 35.46 | 2.9 | 2.88 | |||||
Tangible Book Value, 3 Yr. CAGR % | 61.29 | 54.06 | 26.53 | -8.71 | -4.27 | |||||
Common Equity, 3 Yr. CAGR % | 61.29 | 54.06 | 26.53 | -8.71 | -4.27 | |||||
Cash From Operations, 3 Yr. CAGR % | 44.1 | 254.03 | 4.97 | -9.56 | -31.7 | |||||
Capital Expenditures, 3 Yr. CAGR % | 26.66 | 53.28 | 26.76 | 21.87 | 21.03 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 86.67 | 88.71 | 22.67 | -46.6 | -55.42 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 172.88 | 63.97 | 10.23 | -46.2 | -51.29 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 71.74 | 45.2 | 24.89 | 15.47 | 11.49 | |||||
Gross Profit, 5 Yr. CAGR % | 98.77 | 57.77 | 28.35 | 17.79 | 12.26 | |||||
EBITDA, 5 Yr. CAGR % | -17.53 | -19.22 | 19.41 | 53.02 | 91.07 | |||||
EBITA, 5 Yr. CAGR % | -21.59 | -16.13 | 17.84 | 46.67 | 209.81 | |||||
EBIT, 5 Yr. CAGR % | -21.59 | -16.13 | 17.84 | 46.67 | 209.81 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -29.23 | -15.04 | 8.46 | 26.64 | 87.74 | |||||
Net Income, 5 Yr. CAGR % | -29.23 | -15.04 | 8.46 | 26.64 | 87.74 | |||||
Normalized Net Income, 5 Yr. CAGR % | -30.64 | -14.3 | 11.85 | 34.76 | 70.6 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -45.28 | -18.21 | 4.89 | 23.02 | 83.9 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | 71.32 | 23.88 | 10.88 | 4.75 | |||||
Inventory, 5 Yr. CAGR % | 15.07 | -0.89 | 5.93 | 11.08 | 8.16 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 27.04 | 23.68 | 30.72 | 44.77 | 28.15 | |||||
Total Assets, 5 Yr. CAGR % | 27.9 | 32.21 | 35.05 | 27.53 | 20.95 | |||||
Tangible Book Value, 5 Yr. CAGR % | 13.7 | 23.59 | 31.18 | 26.42 | 10.58 | |||||
Common Equity, 5 Yr. CAGR % | 13.7 | 23.59 | 31.18 | 26.42 | 10.58 | |||||
Cash From Operations, 5 Yr. CAGR % | -0.15 | -5.11 | -1.46 | 108.41 | -0.19 | |||||
Capital Expenditures, 5 Yr. CAGR % | 7.82 | 6.47 | 23.73 | 32.19 | 32.52 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -1.71 | 7.43 | 37.67 | -6.94 | -17.89 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 0.74 | 8.28 | 68.48 | -12.27 | -18.54 |
- Stock Market
- Equities
- NVCR Stock
- Financials NovoCure Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















